Investigational oral drug combo shows promise for newly diagnosed multiple myeloma

The investigational drug ixazomib taken orally in combination with lenalidomide and dexamethasone shows promise in patients with newly diagnosed multiple myeloma, according to the results of a phase 1/2 study. "The all-oral combination of weekly ixazomib plus lenalidomide and dexamethasone was generally well tolerated and appeared active in patients with newly diagnosed multiple myeloma," the lead author says. "Our results support the development of a phase 3 trial studying this combination for ...